STAT Plus: Unbowed by critics, Gilead’s cancer chief pushes ahead with growth plans
HYACINTH EMPINADO/STAT
Gilead Sciences spent years and billions of dollars to build its oncology business, most notably by acquiring Kite Pharma. But that has yet to deliver commercially.
.png)
No hay comentarios:
Publicar un comentario